-$0.15 EPS Expected for XBiotech Inc (NASDAQ:XBIT) This Quarter

Share on StockTwits

Equities research analysts expect XBiotech Inc (NASDAQ:XBIT) to report earnings per share of ($0.15) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for XBiotech’s earnings. XBiotech reported earnings of ($0.16) per share during the same quarter last year, which indicates a positive year over year growth rate of 6.3%. The business is scheduled to issue its next earnings report on Thursday, August 8th.

On average, analysts expect that XBiotech will report full-year earnings of ($0.61) per share for the current financial year. For the next year, analysts anticipate that the business will report earnings of ($0.85) per share. Zacks’ EPS calculations are an average based on a survey of analysts that cover XBiotech.

XBiotech (NASDAQ:XBIT) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter.

A number of equities research analysts have recently weighed in on the company. BidaskClub raised XBiotech from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 22nd. Piper Jaffray Companies assumed coverage on XBiotech in a research note on Friday, June 14th. They issued an “overweight” rating and a $13.00 price objective for the company.

NASDAQ:XBIT traded up $0.10 on Friday, reaching $7.39. The company’s stock had a trading volume of 5,715 shares, compared to its average volume of 242,893. XBiotech has a 12-month low of $2.13 and a 12-month high of $11.74. The firm has a market capitalization of $263.60 million, a price-to-earnings ratio of -12.63 and a beta of 0.47. The company has a 50 day moving average of $8.21.

In related news, major shareholder Fondation Rennes bought 1,200,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was purchased at an average cost of $8.25 per share, with a total value of $9,900,000.00. Following the purchase, the insider now directly owns 5,110,282 shares of the company’s stock, valued at approximately $42,159,826.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 33.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of XBiotech by 5.5% during the 3rd quarter. Vanguard Group Inc. now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after acquiring an additional 43,648 shares during the period. Tibra Equities Europe Ltd bought a new position in shares of XBiotech during the 1st quarter valued at approximately $750,000. Birchview Capital LP bought a new position in shares of XBiotech during the 1st quarter valued at approximately $110,000. Finally, Marshall Wace LLP bought a new position in shares of XBiotech during the 1st quarter valued at approximately $682,000. 7.05% of the stock is owned by institutional investors and hedge funds.

XBiotech Company Profile

XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.

Further Reading: Is it Safe to Invest in Commodities?

Get a free copy of the Zacks research report on XBiotech (XBIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

KEYW  vs. Digimarc  Financial Comparison
KEYW vs. Digimarc Financial Comparison
Taiwan Semiconductor Mfg.  and Silicon Motion Technology  Head to Head Review
Taiwan Semiconductor Mfg. and Silicon Motion Technology Head to Head Review
Head to Head Review: On Deck Capital  versus HARGREAVES LANS/ADR
Head to Head Review: On Deck Capital versus HARGREAVES LANS/ADR
Reviewing Her Imports  & CHURCHILL CAP C/SH
Reviewing Her Imports & CHURCHILL CAP C/SH
ASE Technology  & ReneSola  Financial Comparison
ASE Technology & ReneSola Financial Comparison
Arvinas  versus Innate Pharma  Head-To-Head Review
Arvinas versus Innate Pharma Head-To-Head Review


© 2006-2019 Ticker Report